arrow
M

Michael A. Golafshar

Mayo Clinic
H指数:15
被引数:1,008

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact on outcomes of ultra hypofractionation or hypofractionation regimens and proton or Xrays therapy in a phase III randomized controlled trial MC1635

超低分割或低分割方案以及质子或X射线疗法对结果的影响:一项III期随机对照试验MC1635

2025-08-070
OA
Germline Genetic Testing in Patients with Bone and Soft Tissue Sarcoma: A Prospective Multicenter Study to Evaluate Cancer Susceptibility

骨与软组织肉瘤患者中的生殖细胞系遗传学检测:一项评估癌症易感性的前瞻性多中心研究

2025-03-210
OA
Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial
2025-02-010
OAAI
Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery
2024-03-016
OAAI
Universal genetic testing for hereditary cancer syndromes in an under-represented minority population
2023-04-041
PRE
A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients
2023-01-013
PRE
Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma
2022-07-0145
PRE
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study
2022-03-0144
PREAI
Ultra-accelerated photon, proton, and brachytherapy partial breast irradiation: Primary results of the Mayo 3-fraction trial
2022-02-150
PRE
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
2021-12-2040
OAAI
Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
2021-10-0110
OAAI
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
2021-08-1141
OAAI